Gregory A Otterson

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Anne S Tsao, Melissa Lynne Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael D Offin, Mariano Provencio Pulla, Jeffrey Clarke, Maen Hussain, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan Wade Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Dwight H Owen, Brooke Benner, Lai Wei, Vineeth K Sukrithan, Ashima Goyal, Ye Zhou, Carly Pilcher, Sheryl-Ann Suffren, Gwen Christenson, Nancy Curtis, Megan Jukich, Emily Schwarz, Himanshu Savardekar, Ruthann Norman, Sarah Ferguson, Barbara Kleiber, Robert Wesolowski, William E Carson, Gregory A Otterson, Claire F Verschraegen, Manisha H Shah, Bhavana Konda
A phase 2 clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Michael J Boyer, Mehmet A N Şendur, Delvys Rodriguez Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran Fulden Yumuk, Francisco J Orlandi, Ticiana A Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, null null
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (21) (2021)